Doxorubicin HCl 10mg/vial, 20mg/vial, 50mg/vial; pwd for IV inj after reconstitution; contains lactose. Risk of cardiomyopathy (including left ventricular failure), arrhythmias. Pre-existing heart ...

Race Oncology has been given ethics approval for a Phase I trial of RC220 bisantrene alone and in combination with ... Read ...

LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that Stephen ...

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and ...

Race Oncology Ltd (ASX:RAC) has been approved for its Phase One trial of its chemotherapeutic candidate RC220 to treat people ...

The British biotechnology firm Avacta Therapeutics has reported significant progress with its lead drug candidate AVA6000, a modified form of the chemotherapy drug doxorubicin. In a recently ...

doxorubicin and prednisone (R-CHP) compared to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) alone, for the treatment of patients with previously untreated ...

Discover all the brand names or Trade names of generic drug called Doxorubicin. This serves as a crucial reference for healthcare professionals, patients, caregivers, and anyone looking to ...

Brukinsa plus R-CHOP demonstrated high efficacy and durable responses in double-expressor lymphoma, with manageable safety, supporting further phase 3 trials.